Appendix B

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Multiple Technology Appraisal (MTA)

Colistimethate sodium powder and tobramycin powder for inhalation for the treatment of pseudomonas lung infection in cystic fibrosis

Matrix of consultees and commentators

Consultees	**Commentators (no right to submit or appeal)**
Manufacturers/sponsors • Forest Laboratories UK (colistimethate sodium powder for inhalation) • Novartis (Tobramycin inhalation powder and podhaler) • PH&T pharma (Turbospin) Patient/carer groups • Action for Children • Action for Sick Children • Afiya Trust • Association for Children with Life Threatening or Terminal Conditions • Black Health Agency • British Lung Foundation • Children's Society • Chinese National Healthy Living Centre • Cystic Fibrosis Trust • Equalities National Council • Muslim Council of Britain • Muslim Health Network • National Children's Bureau • National Parent Partnership Network • South Asian Health Foundation • Specialised Healthcare Alliance • WellChild Professional groups • Association of Chartered Physiotherapists in Respiratory Care • Association of Respiratory Nurse Specialists • British Paediatric Respiratory Society	General • Association of British Healthcare Industries • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Commissioning Support Appraisals Service • Department of Health, Social Services and Public Safety for Northern Ireland • EUCOMED • Medicines and Healthcare products Regulatory Agency • National Association of Primary Care • NHS Alliance • NHS Commercial Medicines Unit • NHS Confederation • NHS Quality Improvement Scotland • Public Health Wales NHS Trust • Scottish Medicines Consortium Comparator manufacturer(s) • Gilead (aztreonam) • Novartis (tobramycin for nebulised inhalation) • Profile Pharma (colistimethate sodium for nebulised inhalation) Relevant research groups • Cochrane Airways Group • Cochrane Cystic Fibrosis & Genetic Disorders Editorial Base • MRC Clinical Trials Unit • National Institute for Health Research

Appendix B

Consultees	**Commentators (no right to submit or appeal)**
• British Thoracic Society • Chartered Society of Physiotherapy • Primary Care Respiratory Society UK • Royal College of General Practitioners • Royal College of Nursing • Royal College of Paediatrics & Child Health • Royal College of Pathologists • Royal College of Physicians • Royal Pharmaceutical Society • Royal Society of Medicine • United Kingdom Clinical Pharmacy Association <u>Others</u> • Department of Health • NHS Westminster • Vale of Glamorgan LHB • Welsh Assembly Government	<u>Assessment Group</u> • National Institute for Health Research Health Technology Assessment Programme • School of Health & Related Research Sheffield (ScHARR) <u>Associated Guideline Groups</u> • National Clinical Guidelines Centre • National Collaborating Centre for Women and Children's Health <u>Associated Public Health Groups</u> • None

NICE is committed to promoting equality and eliminating unlawful discrimination. Please let us know if we have missed any important organisations from the lists contained within the matrix and which organisations we should include who have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

Definitions:

Consultees
Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Assembly Government and relevant NHS organisations in England.

The manufacturer/sponsor of the technology is invited to make an evidence submission, respond to consultations and has the right to appeal against the Final Appraisal Determination (FAD).

All non-manufacturer/sponsor consultees are invited to submit a statement[1], respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

Commentators
Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; NHS Quality Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Information Authority and NHS Purchasing and Supplies Agency, and the *British National Formulary*.

All non-manufacturers/sponsors commentators are invited to nominate clinical specialists or patient experts.

Assessment Group (ERG)
An independent academic group commissioned by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme) to assist the Appraisal Committee in reviewing the manufacturer/sponsor evidence submission to the Institute.

[1] Non manufacturer consultees are invited to submit statements relevant to the group they are representing.